NRC Health
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRC research report →
Price Chart
About the company
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning.
- CEO
- Trent Green
- IPO
- 2013
- Employees
- 357
- HQ
- Lincoln, NE, US
Get TickerSpark's AI analysis on NRC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $491.75M
- P/E
- 83.12
- Fwd P/E
- 24.80
- PEG
- -1.26
- P/S
- 3.51
- P/B
- 73.33
- EV/EBITDA
- 24.70
- Div Yield
- 2.75%
- Gross Margin
- 66.79%
- Op Margin
- 10.53%
- Net Margin
- 4.18%
- ROE
- 48.46%
- ROIC
- 8.75%
Latest fiscal year · YoY change
- Revenue
- $137.39M-4.0%
- Gross Profit
- $77.39M-10.1%
- Op Income
- $22.59M
- Net Income
- $11.60M-53.2%
- EPS
- $0.52-50.5%
- OCF Growth
- -23.6%
- FCF Growth
- -17.9%
- 52W High
- $23.68
- 52W Low
- $11.01
- 50D MA
- $20.78
- 200D MA
- $18.19
- Beta
- 0.37
- RSI (14)
- 57
- Avg Volume
- 127.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NRC Health said Q4 and 2025 showed improving TRCV momentum, stable profitability, and a setup for revenue growth to follow in 2026.· February 3, 2026
- Q4 revenue was $35.2 million, down 5% year over year but up 2% sequentially; adjusted EBITDA was $8.7 million and adjusted EPS was $0.16.
- TRCV reached $144.1 million, up 8% year over year and 2% sequentially, marking the fifth straight quarter of sequential TRCV growth.
- Full-year 2025 revenue was $137.4 million, down 4%, while adjusted EBITDA was $40.2 million with a 29% margin and adjusted EPS of $0.93.
- Management said full-year new sales increased 86% year over year and customer retention hit a 7-year high in gross dollar retention.
- The company emphasized growth drivers in enablement, AI-enabled product innovation, cross-sell, retention improvement, and new logo expansion.
Q4 2025 revenue was $35.2 million, down 5% year over year and up 2% sequentially. Adjusted EBITDA was $8.7 million, adjusted net income was $3.4 million, and adjusted EPS was $0.16 per share. TRCV was $144.1 million, up 8% year over year and 2% sequentially. Full-year 2025 revenue was $137.4 million, down 4% from 2024; adjusted EBITDA was $40.2 million with a 29% margin; adjusted net income was $20.7 million and adjusted EPS was $0.93. Management did not provide numerical next-quarter or full-year revenue/EPS guidance, but said the 8% TRCV growth in 2025 gives them confidence revenue growth will follow in 2026.
Trent Green framed the quarter as another period of strong execution, pointing to improved sales coverage, stronger customer success, and product investment as the drivers behind TRCV growth. He emphasized NRC’s value proposition around trust, expertise, and portfolio breadth, including 74% of the top 100 health systems served and an NPS of 68. His tone was confident and forward-looking, especially about 2026 catalysts such as the go-to-market restructure, enablement solutions like Rounding, AI-driven product innovation, cross-sell, retention improvement, and new logo growth.
Shane Harrison highlighted that Q4 revenue of $35.2 million was affected by an easy comparison issue from heavy TRCV attrition recognized in late 2024, while sequential growth showed improving momentum. He underscored the financial profile: 99% recurring revenue, $40.2 million of 2025 adjusted EBITDA at a 29% margin, and efficient free cash flow generation. He also pointed to capital allocation priorities of investing in the business, paying a $0.12 quarterly dividend, repurchasing shares opportunistically, and keeping flexibility for accretive acquisitions.
There was no real analyst Q&A section in the transcript; the call ended after prepared remarks. The main management answers came in the form of commentary that revenue should improve in 2026 as TRCV growth translates into top-line growth, and that margin expansion remains possible as revenue recovers. Management also explained that Q4 expenses were higher because the annual HUB Conference moved into Q4 this year versus Q3 last year.
The bullish case is that NRC is seeing sustained TRCV improvement, with 8% year-over-year growth and five straight quarters of sequential gains. Management also said new sales rose 86% for the full year and retention reached a 7-year high, while newer areas like Rounding showed strong momentum and AI features are being added.
The main bear case is that reported revenue still declined 5% in Q4 and 4% for the full year, showing that TRCV improvement has not yet fully flowed through. Management also flagged difficult comparisons from prior attrition and said retention still has room to improve despite the recent high, while growth depends on execution of the go-to-market restructure and deeper adoption of newer products.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.5%
- Shares Outstanding
- 22.54M
- Float Shares
- 11.84M
of shares held by institutions
121 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kayne Anderson Rudnick Investment Management LLC | 2.03M | ▼ 605.86K |
| Blackrock, Inc. | 1.06M | ▲ 85.50K |
| Morgan Stanley | 859.27K | ▼ 142.61K |
| Vanguard Group Inc | 831.38K | ▼ 90.03K |
| Vanguard Capital Management LLC | 666.55K | ▲ 3.72K |
| Dimensional Fund Advisors LP | 491.23K | ▲ 1.49K |
| Willis Investment Counsel | 434.79K | ▲ 210.15K |
| Geode Capital Management, LLC | 420.06K | ▲ 26.21K |
| Qv Investors Inc. | 372.50K | ▼ 8.81K |
| Farmers & Merchants Investments Inc | 330.65K | ▲ 330.55K |
| Renaissance Technologies LLC | 325.38K | ▼ 15.40K |
| Heartland Advisors Inc | 300.00K | ▲ 62.85K |
Held by 143 ETFs
Biggest fund positions in NRC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Berwick Donald M | other | 7,697 |
| Jun 23, 26 | Bhandari Parul | other | 7,697 |
| Jun 23, 26 | Lockhart Stephen H | other | 7,697 |
| Jun 23, 26 | NUNNELLY JOHN N | other | 7,697 |
| Jun 23, 26 | Wheeler Penny Ann | other | 7,697 |
| Mar 12, 26 | Rau Jason Russell | other | 60,000 |
| Feb 17, 26 | HARRISON SHANE R | buy | 8,000 |
| Jan 22, 26 | Lockhart Stephen H | other | 8,819 |
| Jan 22, 26 | Bhandari Parul | other | 8,819 |
| Dec 29, 25 | HARRISON SHANE R | other | 21,271 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRC coverage
Recent articles, reports, and earnings notes.
No research on NRC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRC report →Terrestrial Energy Reports Second Quarter 2026 Results
gurufocus.com · Aug 11
NRC Down 8% Despite Q2 Earnings Rising Y/Y on TRCV Growth
zacks.com · Aug 3
NRC Health (NRC) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 29
National Research Q2 Earnings Call Highlights
marketbeat.com · Jul 28
NRC Health Announces Second Quarter 2026 Results
businesswire.com · Jul 28
Nations Royalty Reports Fiscal 2026 Year-End Results and Provides Portfolio Update
newsfilecorp.com · Jul 28
90,182 Shares in National Research Corporation $NRC Bought by Fifth Third Bancorp
defenseworld.net · Jul 24
Terra Innovatum Initiates NRC Preapplication Readiness Review to Support Solo™ Construction Permit Application
globenewswire.com · Jul 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.